These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 30665517)

  • 1. Lung function outcomes in the INPULSIS
    Brown KK; Flaherty KR; Cottin V; Raghu G; Inoue Y; Azuma A; Huggins JT; Richeldi L; Stowasser S; Stansen W; Schlenker-Herceg R; Maher TM; Wells AU
    Respir Med; 2019 Jan; 146():42-48. PubMed ID: 30665517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.
    Kreuter M; Wuyts WA; Wijsenbeek M; Bajwah S; Maher TM; Stowasser S; Male N; Stansen W; Schoof N; Orsatti L; Swigris J
    Respir Res; 2020 Jan; 21(1):36. PubMed ID: 32000772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis.
    Flaherty KR; Kolb M; Vancheri C; Tang W; Conoscenti CS; Richeldi L
    Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.
    Richeldi L; Kolb M; Jouneau S; Wuyts WA; Schinzel B; Stowasser S; Quaresma M; Raghu G
    BMC Pulm Med; 2020 Jan; 20(1):3. PubMed ID: 31914963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.
    Wuyts WA; Kolb M; Stowasser S; Stansen W; Huggins JT; Raghu G
    Lung; 2016 Oct; 194(5):739-43. PubMed ID: 27377558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib.
    Richeldi L; Crestani B; Azuma A; Kolb M; Selman M; Stansen W; Quaresma M; Stowasser S; Cottin V
    Respir Med; 2019 Sep; 156():20-25. PubMed ID: 31404749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
    Richeldi L; du Bois RM; Raghu G; Azuma A; Brown KK; Costabel U; Cottin V; Flaherty KR; Hansell DM; Inoue Y; Kim DS; Kolb M; Nicholson AG; Noble PW; Selman M; Taniguchi H; Brun M; Le Maulf F; Girard M; Stowasser S; Schlenker-Herceg R; Disse B; Collard HR;
    N Engl J Med; 2014 May; 370(22):2071-82. PubMed ID: 24836310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis.
    Jouneau S; Crestani B; Thibault R; Lederlin M; Vernhet L; Valenzuela C; Wijsenbeek M; Kreuter M; Stansen W; Quaresma M; Cottin V
    Respir Res; 2020 Nov; 21(1):312. PubMed ID: 33239000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON.
    Song JW; Ogura T; Inoue Y; Xu Z; Quaresma M; Stowasser S; Stansen W; Crestani B
    Respirology; 2020 Apr; 25(4):410-416. PubMed ID: 31329360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subgroup Analysis for Chinese Patients Included in the INPULSIS
    Xu Z; Li H; Wen F; Bai C; Chen P; Fan F; Hu N; Stowasser S; Kang J
    Adv Ther; 2019 Mar; 36(3):621-631. PubMed ID: 30729456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subgroup analysis of Asian patients in the INPULSIS
    Taniguchi H; Xu Z; Azuma A; Inoue Y; Li H; Fujimoto T; Bailes Z; Schlenker-Herceg R; Kim DS
    Respirology; 2016 Nov; 21(8):1425-1430. PubMed ID: 27399197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.
    Costabel U; Inoue Y; Richeldi L; Collard HR; Tschoepe I; Stowasser S; Azuma A
    Am J Respir Crit Care Med; 2016 Jan; 193(2):178-85. PubMed ID: 26393389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
    Richeldi L; Cottin V; du Bois RM; Selman M; Kimura T; Bailes Z; Schlenker-Herceg R; Stowasser S; Brown KK
    Respir Med; 2016 Apr; 113():74-9. PubMed ID: 26915984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities.
    Glaspole I; Bonella F; Bargagli E; Glassberg MK; Caro F; Stansen W; Quaresma M; Orsatti L; Bendstrup E
    Respir Res; 2021 Apr; 22(1):125. PubMed ID: 33902584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume.
    Kolb M; Richeldi L; Behr J; Maher TM; Tang W; Stowasser S; Hallmann C; du Bois RM
    Thorax; 2017 Apr; 72(4):340-346. PubMed ID: 27672117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
    Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
    Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
    Flaherty KR; Wells AU; Cottin V; Devaraj A; Walsh SLF; Inoue Y; Richeldi L; Kolb M; Tetzlaff K; Stowasser S; Coeck C; Clerisme-Beaty E; Rosenstock B; Quaresma M; Haeufel T; Goeldner RG; Schlenker-Herceg R; Brown KK;
    N Engl J Med; 2019 Oct; 381(18):1718-1727. PubMed ID: 31566307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials.
    Azuma A; Taniguchi H; Inoue Y; Kondoh Y; Ogura T; Homma S; Fujimoto T; Sakamoto W; Sugiyama Y; Nukiwa T
    Respirology; 2017 May; 22(4):750-757. PubMed ID: 27997064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis.
    Kreuter M; Costabel U; Richeldi L; Cottin V; Wijsenbeek M; Bonella F; Bendstrup E; Maher TM; Wachtlin D; Stowasser S; Kolb M
    Respiration; 2018; 95(5):317-326. PubMed ID: 29414827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.